Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 6 records per page: next > | last >>
pages: 1 2 3 4 5 6 presentations: 1 to 25 of 146
Introduction: A brief overview of adipose tissue metabolism
Ernst R Lengyel
Univ. of Chicago, Chicago, IL, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Paracrine role of mammary adipocytes in breast cancer progression and drug resistance
Catherine Muller
Institut de Pharmacologie et de Biologie Structurale, Toulouse, France
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
The contribution of adipose fatty acid binding protein in cancer progression
Bing Li
Univ. of Louisville School of Medicine, Louisville, KY, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Adipose stromal cell role in EMT and chemoresistance
Mikhail Kolonin
The University of Texas Health Science Center at Houston, Houston, TX, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Cancer and obesity: Stromal contributions of adipocytes to cancer progression
Philipp E. Scherer
UT Southwestern Medical Ctr., Dallas, TX, United States
from AACR Annual Meeting 2019 on March 30, 2019 1:00 PM-3:00 PM
Chairperson
Nicholas Mitsiades
Baylor College of Medicine,
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium
Simon Kreutzfeldt
National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
p97/VCP: A novel interactor of the sodium iodide symporter, which can be pharmacologically targeted to increase radioiodine uptake in thyroid and breast cancer cells
Alice Fletcher
University of Birmingham, Birmingham, United Kingdom
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Novel clinical targets revealed by kinome reprogramming in mutant ESR1 metastatic breast cancer
Derek Dustin
Baylor College of Medicine, Houston, TX, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER
Tinya J Abrams
Novartis, Cambridge, MA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
FOXA1 chromatin binding is regulated by LSD1-mediated methylation in prostate cancer cells
Changmeng Cai
University of Massachusetts Boston, Boston, MA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
The androgen receptor antagonist darolutamide shows strong antitumor efficacy in patient- and cell line-derived xenograft prostate cancer models
Bernard Haendler
Bayer AG, Berlin, Germany
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target
Elisabetta Marangoni
Inst. Curie, Paris, France
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Epigenomic approaches to identify transcriptional dependencies in prostate cancer
Qianben Wang
Duke University, Durham, NC, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:15 PM
Cistrome mining for new therapeutic targets in hormone-dependent cancers
Myles A Brown
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:15 PM
Long-range epigenetic control of estrogen-responsive transcription
Tim Hui-Ming Huang
UT Health Science Ctr. at San Antonio, San Antonio, TX, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:15 PM
Reducing age associated radiation and chemotherapy normal tissue injury
Bryan G Allen
Univ. of Iowa Hospitals and Clinics, Iowa City, IA, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:30 PM
Non-mutational effects of radiation on ageing
Ken Raj
Public Health England, London, United Kingdom
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:30 PM
Rescue of cognitive function following fractionated brain irradiation in a novel preclinical glioma model
Susanna Rosi
University of California, San Francisco, San Francisco, CA, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:30 PM
Overview of thyroid cancer: Epidemiology to state-of art standard of care
Steven I. Sherman
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
Cancer genomics: Well to poorly differentiated thyroid carcinoma
James A Fagin
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
Discovering targeted therapies of thyroid cancer using drosophila models
Ross L Cagan
Mount Sinai School of Medicine, New York, NY, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
BRAF-targetedtherapy and mechanisms of resistance in thyroid cancer clinical trials
Manisha H Shah
Ohio State Univ. Comp. Cancer Ctr., Columbus, OH, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
Emerging novel RET-Targeted therapy in thyroid cancer
Lori J Wirth
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer
Maysoun Shomali
Sanofi, Cambridge, MA, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
<< first | < prev page: of 6 records per page: next > | last >>
pages: 1 2 3 4 5 6 presentations: 1 to 25 of 146